TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a current biopsy-confirmed NASH within 6 months of screening or a suspected diagnosis of NAFLD/NASH~* Screening magnetic resonance imaging-proton density fat fraction (MRI-PDFF) with ≥10% liver steatosis~* Fasting serum low density lipoprotein-cholesterol (LDL-C) \>130 mg/dL at Screening, \>110 mg/dL on lipid-lowering medications~Key Exclusion Criteria:~* Body mass index (BMI) \<25 kg/m2~* Fibrosis-4 index (Fib-4) \>2.6~* Any of the following laboratory abnormalities:~  1. alanine aminotransferase (ALT) \>5 × upper limit of normal (ULN) or aspartate aminotransferase (AST) \>5 × ULN~ 2. International normalized ratio (INR) ≥1.3, unless on anticoagulant therapy~ 3. Total bilirubin \>ULN, except with an established diagnosis of Gilbert's syndrome~ 4. Platelet count less than the lower limit of normal (LLN)~ 5. Creatinine clearance as calculated by the modification of diet in renal disease (MDRD) estimated glomerular filtration rate (eGFR) equation \<60 mL/min~* Uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) \>9.5%~* Clinical hyperthyroidism or hypothyroidism or screening hormone results pointing to thyroid dysfunction.~* Uncontrolled hypertension~* Participants with known intolerance to MRI or with conditions contraindicated for MRI procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elobixibat (Type: EXPERIMENTAL): Elobixibat 5 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Delirium Treatment With Acupuncture in Internal Medicine Departments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized in internal medicine department~* Aged over 65 years~* Delirium or subsyndromal delirium within the last 48 hours~Exclusion Criteria:~* Platelet count under 20x10\^9/L~* Encephalopathy explained by a cause other than delirium (acute stroke, alcohol, cirrhosis, etc.)~* History of severe dementia~* Communication barriers preventing delirium assessment

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): Acupuncture for delirium treatment
- Standard care (Type: NO_INTERVENTION): Standard conventional delirium care at the discretion of the department medical staff

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 25-39 years~* First stimulation with rFSH only~* Indication for intrauterine insemination with standard rFSH starting dose~* Regular menstrual bleeding with a cycle between 21-35 days~* Two ovaries~* Bilateral tuba patency~* Semen analysis must be sufficient for insemination according to the diagnostic analysis.~Exclusion Criteria:~* More than three former stimulated intrauterine insemination cycles

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Individual or standard rFSH dose (Type: ACTIVE_COMPARATOR): Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64).
- Standard rFSH dose (Type: ACTIVE_COMPARATOR): Standard dose of rFSH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Stage IIB-IV mycosis fungoides or Sezary syndrome, who have failed at least 1 standard systemic therapy or are not candidates for standard therapy.~2. Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.~3. Age \> 18 years and \<= 75 years.~4. Karnofsky Performance Status \>= 70%.~5. Corrected DLCO \>= 40%~6. Left ventricle ejection fraction (LVEF) \> 30%.~7. ALT and AST must be \<= 3X normal. Total bilirubin \<= 3 mg/dL unless hemolysis or Gilbert's disease.~8. Estimated creatinine clearance \>= 50 ml/min.~9. Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in HLA-A, B, C or DRB1.~10. Signed informed consent.~11. Patients with prior malignancies diagnosed \> 5 years ago without evidence of disease are eligible.~12. Patients with a prior malignancy treated \< 5 years ago but have a life expectancy of \> 5 years for that malignancy are eligible.~Donor Inclusion Criteria~1. Age \>=17.~2. HIV seronegative.~3. No contraindication to the administration of G-CSF.~4. Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate~Exclusion Criteria:~1. Uncontrolled active infection.~2. Uncontrolled congestive heart failure or angina.~3. Pregnancy or nursing patients will be excluded from the study.~4. Those who are HIV-positive will be excluded from the study due to high risk of lethal infection after hematopoietic cell transplantation.~Donor Exclusion Criteria~1. Serious medical or psychological illness.~2. Pregnant or lactating women are not eligible~3. Prior malignancies within the last 5 years except for non-melanoma skin cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total lymphoid irradiation & anti-thymocyte immunoglobulin (Type: EXPERIMENTAL): TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Center for Neurologic Study-Lability Scale (CNS-LS)score of 13 or greater~* Clinical diagnosis of Pseudobulbar Affect (PBA)~* Documentation of Neurologic disease or brain injury~Exclusion Criteria:~* Unstable neurologic disease~* Severe dementia~* Stroke within 3 months~* Penetrating TBI~* Contraindications to Nuedexta~* Severe Depressive Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nuedexta (DM 20 mg/Q 10 mg) (Type: OTHER): Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed week 24 evaluation of Study C935788-047 or Study C935788-048 or discontinued early due to lack of response.~* Able and willing to give written informed consent~Exclusion Criteria:~* Discontinued participation in Study C935788-047 or Study C935788-048 for any reason other than lack of response~* Poorly controlled hypertension during Study C935788-047 or Study C935788-048~* Significant infection, an acute infection such as influenza, or known inflammatory process

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fostamatinib Disodium (Type: EXPERIMENTAL): Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with primary chronic insomnia. Subject is otherwise in good general health, based on screening physical examination and medical history.~Exclusion Criteria:~* Subject has recent history of known clinically significant abnormal laboratory findings.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
- Eszopiclone (Type: EXPERIMENTAL): Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure~* Patients with at least 3 Apfel risk factors for PONV~Exclusion Criteria:~* Patients scheduled to undergo transplant surgery~* Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block~* Patients who are expected to remain ventilated for a period after surgery~* Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APD421 + standard anti-emetic (Type: EXPERIMENTAL): Single dose of IV APD421
- Placebo + standard anti-emetic (Type: PLACEBO_COMPARATOR): Single dose of IV placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 1 diabetes mellitus: Fasting c-peptide \< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis.~2. Using a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily~3. HbA1c of less than 8.5%.~4. Well versed with carbohydrate counting~5. Age 18-75 years~Exclusion Criteria:~1. Type 1 diabetes for less than 12 months;~2. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks;~3. Hepatic disease (transaminase \> 3 times normal) or cirrhosis;~4. Renal impairment (serum creatinine \> 1.5);~5. HIV or Hepatitis C positive status;~6. Participation in any other concurrent clinical trial;~7. Any other life-threatening, non-cardiac disease;~8. Use of an investigational agent or therapeutic regimen within 30 days of study.~9. history of pancreatitis~10. pregnancy~11. inability to give informed consent~12. history of gastroparesis~13. history of medullary thyroid carcinoma or MEN 2 syndrome.~14. Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer~15. Women of childbearing potential who are not using adequate contraception 16) Women who are pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Daily Injection
- Liraglutide 1.8mg (Type: ACTIVE_COMPARATOR): Daily Injection
- Liraglutide 1.2mg (Type: ACTIVE_COMPARATOR): Daily injections
- Liraglutide 0.6 mg (Type: ACTIVE_COMPARATOR): Daily injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* breast cancer~* undergoing unilateral mastectomy with or without axillary node dissection~* received adequate oral and written information about the study and signed an informed-consent form~Exclusion Criteria:~* pregnant or breastfeeding~* known thromboembolic disease or with high risk of thromboembolism, warranting extra anticoagulation in connection with the procedure~* known allergy to tranexamic acid/Cyklokapron®

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- topical tranexamic acid (Type: EXPERIMENTAL): tranexamic acid to be smeared on surgical wounds before closure
- placebo control (Type: PLACEBO_COMPARATOR): saline to be smeared on surgical wounds before closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes.~* Have been treated with one of the following treatment regimens for at least three months prior to screening: \*metformin alone; \*sulfonylurea (SU) alone; \*thiazolidinedione (TZD) alone; \*a combination of metformin and SU; \*a combination of metformin and TZD.~* HbA1c between 7.1% and 10.0%, inclusive.~* Body Mass Index (BMI) \> 25 kg/m\^2 and \< 45 kg/m\^2~Exclusion Criteria:~* Have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental drug, medical, or surgical treatment was given) within 30 days prior to screening.~* Have characteristics contraindicating metformin, SU, or TZD use.~* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.~* Have used any prescription drug to promote weight loss within 3 months prior to screening.~* Are currently treated (for greater than 2 consecutive weeks) with any of the following excluded medications: \*insulin within 3 months prior to screening; \*alpha-glucosidase inhibitors within 3 months prior to screening; \*meglitinides within 3 months prior to screening; \*drugs that directly affect gastrointestinal motility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 - exenatide before breakfast and dinner (Type: EXPERIMENTAL): None
- 2 - exenatide before lunch and dinner (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed supratentorial pure or mixed anaplastic oligodendroglioma~  * Unifocal or multifocal disease~ * Prior suspected or proven low-grade glioma eligible provided biopsy reveals pure or mixed anaplastic oligodendroglioma that has not been previously treated with radiotherapy and/or chemotherapy~* No equivocal oligodendroglial element~* No tumors predominantly located in the posterior fossa (i.e., brainstem or cerebellum)~* No spinal cord tumors~* No evidence of spinal drop metastasis or spread to noncontiguous meninges~PATIENT CHARACTERISTICS:~Age:~* 18 to 65~Performance status:~* Zubrod 0-1~Life expectancy:~* More than 12 weeks~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* Bilirubin no greater than 2 times normal~* Aspartate aminotransferase (AST) no greater than 3 times normal~* Alkaline phosphatase no greater than 2 times normal~Renal:~* Creatinine no greater than 1.5 times normal~Other:~* No active infection~* No other medical problems that would preclude study participation~* No other malignancy within the past 3 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No prior chemotherapy for this malignancy~* No prior temozolomide~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy to the brain, head, or neck~Surgery:~* At least 14 days since prior surgery requiring general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pre-RT temozolomide, RT plus temozolomide (Type: EXPERIMENTAL): Pre-radiation therapy (RT) temozolomide, RT plus temozolomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 infection, confirmed by polymerase chain reaction (PCR) test within 3 days from enrollment~* Only mild and moderate COVID-19 infected cases~* Able to provide informed consent~Exclusion Criteria:~* Unable to take oral medication~* Pregnant or breast feeding lady~* Patients with severe COVID symptoms or admission in ICU/HDU~* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) more than 5 upper limit of normal (ULN)~* On non-invasive positive pressure ventilation or mechanical ventilation at time of study entry~* Known hypersensitivity to Doxycycline or ivermectin or its components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivermectin and Doxycycline (Type: ACTIVE_COMPARATOR): Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
- Placebo (Type: PLACEBO_COMPARATOR): Standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete